Kane Biotech Inc KNBIF

Primary Symbol: V.KNE

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > Some titbit of news...

<< Previous

Bullboard Posts

Next >>

Comment by RoyMax123on Aug 29, 2024 1:04pm

33 Views

Post# 36201504

RE:RE:Some titbit of news...

Yes, I saw that but I wasn't sure if they mean the approval for Revyve or the fact that they obtained the MDSAP certification.

I guess like you said that they will confirm it this afternoon, or it could be a good question to ask.

francoisl13 wrote: It is interesting to note in the article that KNE received the Health Canada approval, I guess they will officially notified the shareholders in today's call.
See excerpt from the Winnipeg FreePress article below;
''It has received approval through Health Canada’s medical device single audit program and is now 'finalizing paper work. Kane does not expect to be able to start shipping in Canada until the end of September, according to CEO Marc Edwards.''